# Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

> **NCT06333652** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 14 (estimated)

## Conditions studied

- Preeclampsia

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT06333652
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333652, "Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06333652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*